[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100659563":3},{"organization":4,"outcomesModule":7,"designInfo":25,"detailedDescription":24,"studyPopulation":24,"armGroups":34,"interventions":60,"overallOfficials":24,"centralContacts":68,"locations":74,"responsibleParty":88,"collaborators":24,"id":90,"slug":91,"hasResults":92,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":24,"eligibilityCriteria":96,"healthyVolunteers":97,"sex":98,"minAge":99,"maxAge":100,"enrollmentInfo":101,"targetDuration":24,"studyType":104,"phases":105,"briefSummary":107,"conditions":108,"keywords":24,"overallStatus":110,"whyStopped":24,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},{"fullName":5,"class":6},"Altis Medicines, Inc","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":24},[9],{"measure":10,"description":11,"timeFrame":12},"Incidence of TEAEs (treatment-emergent adverse events)","To evaluate the safety and tolerability of ALT-01 in healthy participants","From first dose of study drug through End of Study Visit\u002FEarly Termination Visit. End of Study is Day 169.",[14,18,21],{"measure":15,"description":16,"timeFrame":17},"PK Parameters -- Tmax","To evaluate the Pharmacokinetics parameters through plasma concentration - Time to Maximum Concentration (Tmax)","From first dose of study drug through End of Study\u002FEarly Termination Visit. End of Study is Day 169.",{"measure":19,"description":20,"timeFrame":17},"PK Parameters -- AUC","To evaluate the PK parameters through plasma concentration- Area Under the Curve (AUC)",{"measure":22,"description":23,"timeFrame":17},"PK Parameters -- Cmax","To evaluate the PK parameters through plasma concentration- Maximum Concentration (Cmax)",null,{"allocation":26,"interventionModel":27,"interventionModelDescription":24,"primaryPurpose":28,"observationalModel":24,"timePerspective":24,"maskingInfo":29},"RANDOMIZED","SEQUENTIAL","TREATMENT",{"masking":30,"maskingDescription":24,"whoMasked":31},"DOUBLE",[32,33],"PARTICIPANT","INVESTIGATOR",[35,42,45,48,51,54,57],{"label":36,"type":37,"description":38,"interventionNames":39},"ALT-01 Dose A","EXPERIMENTAL","Subcutaneous injection",[40,41],"Drug: ALT-01","Drug: Placebo",{"label":43,"type":37,"description":38,"interventionNames":44},"ALT-01 Dose B",[40,41],{"label":46,"type":37,"description":38,"interventionNames":47},"ALT-01 Dose C",[40,41],{"label":49,"type":37,"description":38,"interventionNames":50},"ALT-01 Dose D",[40,41],{"label":52,"type":37,"description":38,"interventionNames":53},"ALT-01 Dose E",[40,41],{"label":55,"type":37,"description":38,"interventionNames":56},"ALT-01 Dose F",[40,41],{"label":58,"type":37,"description":38,"interventionNames":59},"ALT-01 Dose G",[40,41],[61,65],{"type":62,"name":63,"description":38,"armGroupLabels":64,"otherNames":24},"DRUG","ALT-01",[36,43,46,49,52,55,58],{"type":62,"name":66,"description":38,"armGroupLabels":67,"otherNames":24},"Placebo",[36,43,46,49,52,55,58],[69],{"name":70,"role":71,"phone":72,"phoneExt":24,"email":73},"Altis Study Director","CONTACT","617-302-6406","info@altismedicines.com",[75],{"facility":76,"status":24,"city":77,"state":78,"zip":79,"country":80,"countryCode":81,"cosmosGeoPoint":82,"geoPoint":87,"contacts":24},"Altis Site","Adelaide","South Australia","5000","Australia","AU",{"type":83,"coordinates":84},"Point",[85,86],138.59863,-34.92866,{"lat":86,"lon":85},{"type":89,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100659563","phase-1-first-in-human-randomized-blinded-placebo-controlled-single-ascending-dose-study-of-alt-01-in-healthy-participants-100659563",false,"NCT07865442","First in Human Study of ALT-01 in Healthy Participants","First in Human, Randomized, Blinded, Placebo-Controlled Single Ascending Dose Study of ALT-01 in Healthy Participants","Key Inclusion Criteria:\n\n1. Willingness to provide written informed consent and comply with the intervention and all study assessments\n2. Age 18 to 65\n3. Body mass index (BMI) ≥ 18 to 32 kg\u002Fm2\n4. Healthy adults\n\nKey Exclusion Criteria:\n\n1. Women who are pregnant or lactating\n2. Participation in any other investigational drug study and received the last dose of investigational drug within 30 days or 5 half-lives (whichever is longer)\n3. Donation or loss of ≥ 450 mL of blood, platelets or plasma within 3 months prior to randomization\n4. Any condition that prevents the participant from complying with study procedures",true,"ALL","18 Years","65 Years",{"count":102,"type":103},50,"ESTIMATED","INTERVENTIONAL",[106],"PHASE1","The primary objective of the study is to evaluate the safety and tolerability of ALT-01 in healthy participants",[109],"Autoimmune Disease","NOT_YET_RECRUITING","2026-10-07",{"date":113,"type":114},"2026-10-13","ACTUAL",{"date":116,"type":103},"2026-10-26",{"date":118,"type":103},"2027-09-30",{"name":5,"class":6},1]